First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
Telix Pharmaceuticals has begun dosing patients in its OPTIMAL-e Phase 2 trial assessing TLX597-Tx, a new PSMA-targeted radioligand therapy, for metastatic hormone-sensitive prostate cancer. This adaptive study aims to improve treatment efficacy and quality of life by personalizing therapy based on disease response. The trial builds on previous stu…